Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PARP inhibitor

- PMLiVE

Nexium windfall lifts AZ in third quarter

Still to feel effects of generic competition

- PMLiVE

AZ advances immuno-oncology ambitions

Buys imaging company and signs PD-1 collaborations with Pharmacyclics and J&J

- PMLiVE

AZ to work with UK university on drug delivery technologies

Company's staff will also teach parts of courses at The University of Manchester

- PMLiVE

Orphan drugs lead CHMP recommendations

Clinuvel's Scenesse is first drug set for European approval to treat rare intolerance to sunlight

AstraZeneca AZ global R&D corporate HQ

AstraZeneca cements links with Cambridge University

Agrees a series of collaborations in areas such as Alzheimer's and multiple sclerosis

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

AZ: We have to be able to show mHealth can work

Still room for improvement in mobile health, Andy Jones tells ThinkDigital

- PMLiVE

Iressa blood test nears approval in Europe

Diagnostic for AZ's lung cancer drug is less invasive than current tumour biopsy method

- PMLiVE

AZ sets up joint lab with Cancer Research UK

Five-year collaboration will drive charity’s research programmes

- PMLiVE

FDA approves AZ’s opioid-induced constipation drug Movantik

Trials showed positive reactions to the treatment

- PMLiVE

AZ and Lilly set up BACE camp for Alzheimer’s

Lilly will pay AZ up to $500m in development and regulatory costs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links